2025年9月,林业发展局就误导DTC的药物广告发出50次警告,要求提供准确的风险信息和科学申报。 FDA issues 50 warnings in Sept 2025 over misleading DTC drug ads, demanding accurate risk info and scientific claims.

美国食品和药物管理局在2025年9月发布了50封无标题的信件,针对直接向消费者发送的药品广告,以误导性声明,缺少风险信息,以及宣传未经验证的生活质量益处. The FDA issued 50 untitled letters in September 2025 targeting direct-to-consumer drug ads for misleading claims, missing risk information, and promoting unverified quality-of-life benefits. 该机构利用AI监测跨平台的广告,正在打击夸大图像、没有均衡披露的名人背书以及依赖未经验证的研究。 The agency, using AI to monitor ads across platforms, is cracking down on exaggerated imagery, celebrity endorsements without balanced disclosures, and reliance on non-validated studies. 在不禁止广告的同时,林业发展局要求更严格地遵守标签规则、更快的风险披露和科学上合理的主张,这反映出美国独有的系统更广泛地推动保护消费者免受误导性营销。 While not banning ads, the FDA is demanding stricter compliance with labeling rules, faster risk disclosures, and scientifically sound claims, reflecting a broader push to protect consumers from misleading marketing in a system unique to the U.S.